Akèy › Maladi fwa steatotik › Arizona › Chandler
Etid klinik pou Maladi fwa steatotik nan Chandler, AZ
10 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote Chandler (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
- 89bio Clinical Study Site, Chandler
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
- 89bio Clinical Study Site, Chandler
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
- Arizona Liver Health, Chandler
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Ap rekriteFaz 3
- The Institute for Liver Health II dba Arizona Clinical Trials - Chandler, Chandler
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
- Akero Clinical Study Site, Chandler
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 2
- Arizona Liver Health, Chandler
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Ap rekriteFaz 2
- GSK Investigational Site, Chandler
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, Chandler
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Ap rekriteFaz 2
- GSK Investigational Site, Chandler
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Ap rekrite
- Arizona Liver Health, Chandler
Etid Maladi fwa steatotik nan lòt vil
- San Antonio, TX17 etid
- New York City, NY16 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Richmond, VA12 etid
- Tucson, AZ10 etid
- St. Louis, MO9 etid
- Hialeah, FL9 etid
- Dallas, TX9 etid
- Orlando, FL9 etid
Lòt etid nan Chandler
- Kansè nan tete5 etid
- Kansè Poumon ki pa ti selil5 etid
- Kansè kolorektal5 etid
- Obèsite5 etid
- Maladi Dijestif5 etid
- Maladi fwa4 etid
- Sipwa4 etid
- Dyabèt Tip 24 etid
- Kansè Metastatik4 etid
- Maladi Alzheimer3 etid
- Maladi kadyovaskilè3 etid
- Kansè kolon3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.